Funder: Leukemia & Lymphoma Society
Due Dates: December 6, 2024 (LOI opens) | February 14, 2025 (LOI due) | April 25, 2025 (Full application due, if invited)
Funding Amounts: Up to $150,000 total over 2 years; no indirect costs; no PI salary support; capital equipment >$7,500 not covered.
Summary: Supports new independent investigators conducting impactful research on leukemia or myelodysplastic syndromes (MDS).
Key Information: Applicants must be within 7 years of their first independent faculty position; international applicants eligible.
Description
This program provides funding for new independent investigators to pursue research projects that will have a significant impact on leukemia or myelodysplastic syndromes (MDS). The goal is to support early-career faculty as they establish their research careers in the field of leukemia. The grant is open to researchers worldwide and is intended to foster innovative research that advances understanding, diagnosis, or treatment of leukemia and related disorders.
Due Dates
- December 6, 2024: Letter of intent (LOI) opens
- February 14, 2025 (12pm CT): LOI due via ProposalCentral
- March 21, 2025: Notification if invited to submit a full application
- April 25, 2025 (12pm CT): Full application due (by invitation)
- By June 30, 2025: Grant recipients notified
- Funding cycle begins: July 1, 2025
Funding Amount
- Maximum award: $150,000 total over 2 years
- No indirect costs or institutional overhead
- No salary support for the principal investigator
- Capital equipment purchases above $7,500 are not covered (exceptions require justification)
- Research travel: Up to $3,000 allowed
- All other project support and funding sources must be disclosed
Eligibility
Eligible Applicants
- Independent investigators at non-profit academic institutions
- Within 7 years of their first independent faculty-level position (excluding training years such as residency, fellowship, or postdoc)
- Must have dedicated lab space, authority to hire/supervise personnel, and control over research activities and grant funds
- Adjustments for career interruptions (e.g., family leave, military service, illness) are possible with documentation
- International applicants welcome; U.S. citizenship is not required
- Applicants with KO8, R00, or R99 grants are eligible (these do not count toward the $175K/year direct cost threshold)
- Applicants with DOE, DOD, NSF, R21, or other grants under $175K/year direct costs are eligible
- Only one LOI per applicant
Not Eligible
- Applicants with active grants totaling $175,000 or more in direct costs per year (excluding KO8, R00, R99)
- Fellows, or those with NIH RO1, VA Merit Award, or equivalent funding
- Previous recipients of this new investigator award
- Renewal applications
- Co-PI applications
Application Process
-
Letter of Intent (LOI):
- Submit via ProposalCentral by February 14, 2025, 12pm CT.
- The LOI is used to assess eligibility and project fit.
- Only applicants invited after LOI review may submit a full application.
-
Full Application:
- If invited, submit the full application by April 25, 2025, 12pm CT.
- Instructions and a link will be provided via email.
-
Review:
- Applications are reviewed by the Leukemia Research Foundation’s independent Medical Advisory Board.
- No written feedback is provided due to volume.
-
Notification:
- Awardees will be notified by June 30, 2025.
-
Start of Funding:
Additional Information
- Only one LOI per applicant is permitted.
- Minority and underrepresented applicants are encouraged to apply.
- All support for the project (including overlapping funding) must be disclosed.
- For technical issues with ProposalCentral, contact pcsupport@altum.com or 800.875.2562.
External Links
Contact Information